Avvinity is a joint venture between Horizon Discovery and Centauri Therapeutics. Their portfolio includes antibodies, antibody fragments, RNA/DNA, Aptamers, and small molecules as targeting domains. Their technology harnesses the natural immune adaptation of humans and primates to develop novel treatments for solid tumors and leukemia. Avvinity's immunotherapeutics have the potential to revolutionize cancer treatment in healthcare institutes.